Conference Coverage EAS 2019 See All Content See past conferences Maastricht, The Netherlands May 26, 2019 May 29, 2019 News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Researchers debated the merits of Lp(a)—while one sees the future, another argued in favor of sticking with LDL cholesterol. < > Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019 Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019 News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019 News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019 News Conference News EAS 2019 FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis Michael O'Riordan June 03, 2019 @TCTMD Follow Us
News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Researchers debated the merits of Lp(a)—while one sees the future, another argued in favor of sticking with LDL cholesterol.
Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019
News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News EAS 2019 FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis Michael O'Riordan June 03, 2019